Vol. 9 No. 1 (2017)

Artigos

• Obinutuzumab for the treatment of unfit patients with chronic lymphocytic leukemia: budget impact analysis based on time to next treatment

  Christina Fraga, Rodrigo Shimabukuro Ho, Laura Maria Fogliatto, Camila Souza, Juliana Biondo, Marcia Regina Alves

  2-11

  • PDF (Português (Brasil))

• Cost-effectiveness of dengue vaccination in Brazil

  Laure Durand, Victoria Genovez, Denizar Araujo

  12-29

  • PDF

• Policy strategies that drive the incorporation of technology: Health Technology Assessment in oncology

  Rodrigo Costa, Myrian Fernandes, Orenzio Soler, Ligia Bahia

  30-38

  • PDF (Português (Brasil))

• Brazilian patients multi-institutional consensus on biosimilar drugs

  Priscila Torres, Igor Kos, Andreia Isaac, Nilma Oliveira, Mari Ivone da Silva, Adriana Oliveira, Shaira Caetano, Wilton Drumond, Dayane Ferreira, José Célio Peixoto, Izabel Oliveira, Maria Conceição dos Santos, Iara Kobielski, Abigail Silva, Márcia Marques, Geralda Sá, Julia Leitão, Valderílio Azevedo

  39-43

  • PDF (Português (Brasil))

• Cost-minimization and budget impact analysis of certolizumab pegol for patients with Crohn’s disease, moderate or severe, with relapse after conventional treatment from the perspective of the Brazilian private payer

  Ricardo Rosim, Andreas Duva, André Ferraz, Arcangela Valle, Emese Tóth, Samara Ferguson, Érico Carmo

  44-53

  • PDF

• Secondary hyperparathyroidism treatment costs with cinacalcet or PTX, for uncontrolled patients with conventional clinical therapy under Brazilian Public Health System perspective

  Denizar Araújo, Laura Amaral, Ana Claudia Guersoni, Aluízio Carvalho, Cristina Kahrol, Fabio Montenegro, Leandro Lucca, Elisa Sampaio, Melanie Custódio, Rosa Maria Moyses, Vanda Jorgetti

  54-61

  • PDF (Português (Brasil))

• Health production function for elderlies: the European case

  Marcia Regina Godoy, Cristiane Silva

  62-72

  • PDF (Português (Brasil))

• Custo-efetividade do afatinibe versus pemetrexede associado a cisplatina, erlotinibe e gefitinibe no tratamento de primeira linha de pacientes com câncer de pulmão não pequenas células localmente avançado ou metastático, com mutação do receptor do fa

  Natália Santoni, Thaís Melo, Anna Rita Aguirre, Daniela Veiga, Camila Souza

  73-82

  • PDF (Português (Brasil))

• Cost-effectiveness analysis of abiraterone acetate plus prednisone in the post-androgen deprivation therapy setting followed by enzalutamide in the post-chemotherapy setting versus the opposite treatment sequence in metastatic castration resistant pro

  Lilian Pititto, Elio Asano

  83-92

  • PDF (Português (Brasil))

• Productivity analysis of hospital mergers in Portuguese National Health System

  Alexandre Nunes

  93-99

  • PDF (Português (Brasil))

• Cost-effectiveness analysis of 52 mg levonorgestrel-releasing intrauterine system (LNG-IUS) versus short-acting hormonal contraceptives in avoiding unintended pregnancy (UP) in 15 to 19 year-old adolescents under the Brazilian Public Healthcare System

  Camila Pepe, Mara Sakagute, Natalia Ramos, Carlos Afonso Maestri

  100-108

  • PDF (Português (Brasil))

• Economic analysis of the treatment of venous thromboembolism with rivaroxaban in comparison with enoxaparin plus warfarin under the perspective of the Brazilian Private Healthcare System

  Alexandra Piedade, Luciano Paladini, Diego Kashiura, Teresa Lemmer, Flávia Tobaruella, Karisa Campos

  109-121

  • PDF (Português (Brasil))

• Impact of nutritional therapy on the total cost of hospital accounts

  Adriano Hyeda, Élide Costa

  122-127

  • PDF (Português (Brasil))

• The use of over-the-counter medicines and cost savings generated for health systems: a review

  Antonio Cesar Rodrigues

  128-136

  • PDF (Português (Brasil))

• Cervical cancer in Brazil: a retrospective on public policies for women’s health

  Carolina Tsuchiya, Tatiana Lawrence, Mariana Klen, Roberta Fernandes, Marcia Regina Alves

  137-147

  • PDF (Português (Brasil))